Study of Comprehensive ANd Multimodal Marker-based Cohort of Progressive Supranuclear Palsy(PSP)

NCT05579301 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 130

Last updated 2022-10-13

No results posted yet for this study

Summary

The purpose of this cohort study is to develop a reliable biomarker in progressive nuclear palsy (PSP).

Conditions

Sponsors & Collaborators

  • SMG-SNU Boramae Medical Center

    collaborator OTHER
  • Seoul National University Hospital

    lead OTHER

Principal Investigators

  • Jee-Young Lee, M.D. · SMG-SNU Boramae Medical Center

Eligibility

Min Age
50 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-12-19
Primary Completion
2024-12-19
Completion
2025-02-28

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05579301 on ClinicalTrials.gov